Skip to main content
. 2022 Apr 25;198(2):267–277. doi: 10.1111/bjh.18197

FIGURE 4.

FIGURE 4

Overall survival (OS) for all relapsed/refractory diffuse large B‐cell lymphoma (R/R DLBCL) patients of at most 70 years at relapse who underwent autologous stem cell transplantation (ASCT). (A) Among all patients. (B) Among patients with early relapse (≤12 months from primary diagnosis) and late relapse (>12 months) separately. (C) Among patients aged less than 60 or 60–70 years separately. Patients were followed from date of ASCT until death of any cause